X

Trial Profile

Effects of PCSK9 inhibition by Evolocumab on postprandial lipid metabolism in type 2 diabetes

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 03 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Evolocumab (Primary)
Indications Hypercholesterolaemia; Hypertriglyceridaemia
Focus Therapeutic Use
Acronyms EVOLKIN

Most Recent Events

29 Sep 2023 Results of secondary analysis exploring the hypothesis that significant abnormalities in the metabolism of intestinally derived lipoproteins are present in individuals with type 2 diabetes on statin therapy.published in the Diabetologia
06 Aug 2018 Status changed from recruiting to completed.
07 Jul 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com